Replimune Group (NASDAQ:REPL) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Replimune Group (NASDAQ:REPL) from a neutral rating to a buy rating in a research report sent to investors on Monday morning, Marketbeat Ratings reports. They currently have $12.00 price objective on the stock. HC Wainwright also issued estimates for Replimune Group’s Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($3.42) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.94) EPS.

REPL has been the topic of a number of other research reports. Barclays lowered Replimune Group from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $17.00 to $3.00 in a report on Wednesday, July 23rd. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a report on Monday, October 20th. BMO Capital Markets lowered Replimune Group from an “outperform” rating to an “underperform” rating and lowered their price target for the stock from $27.00 to $2.00 in a report on Wednesday, July 23rd. JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a report on Monday, October 20th. Finally, Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $4.00 to $18.00 in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Replimune Group has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Replimune Group Stock Performance

NASDAQ REPL opened at $10.21 on Monday. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. Replimune Group has a 52-week low of $2.68 and a 52-week high of $17.00. The business’s 50-day moving average price is $5.64 and its 200 day moving average price is $7.37. The firm has a market cap of $796.99 million, a P/E ratio of -3.15 and a beta of 0.42.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). On average, equities research analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of Replimune Group stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares in the company, valued at approximately $721,556.16. This trade represents a 6.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of Replimune Group by 20.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after acquiring an additional 119,145 shares during the period. Exome Asset Management LLC raised its position in shares of Replimune Group by 438.6% during the 1st quarter. Exome Asset Management LLC now owns 294,846 shares of the company’s stock worth $2,875,000 after purchasing an additional 240,108 shares during the last quarter. Moody Aldrich Partners LLC acquired a new position in shares of Replimune Group during the 1st quarter worth approximately $1,925,000. Nuveen LLC acquired a new position in shares of Replimune Group during the 1st quarter worth approximately $6,546,000. Finally, Deutsche Bank AG raised its position in shares of Replimune Group by 0.4% during the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock worth $5,496,000 after purchasing an additional 2,140 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.